{"id":"diquafosol","rwe":[{"pmid":"41804812","year":"2026","title":"Efficacy of Topical Cyclosporine Versus Topical Diquafosol in Treating Dry Eye Disease: A Systematic Review and Meta-Analysis.","finding":"","journal":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","studyType":"Clinical Study"},{"pmid":"41523136","year":"2025","title":"Integrating secretagogues into clinical dry eye care: Insights from Asian clinical experience.","finding":"","journal":"Taiwan journal of ophthalmology","studyType":"Clinical Study"},{"pmid":"41523116","year":"2025","title":"Restoring the mucin barrier: Advances in secretagogue therapies for ocular surface disorders.","finding":"","journal":"Taiwan journal of ophthalmology","studyType":"Clinical Study"},{"pmid":"41464847","year":"2025","title":"Preoperative Diquafosol vs. Intense Pulsed Light with Gland Expression for MGD: Effects on Refractive Accuracy and Tear Film Stability in Cataract Surgery.","finding":"","journal":"Journal of clinical medicine","studyType":"Clinical Study"},{"pmid":"41366894","year":"2025","title":"Comparison of the efficacy of intense pulsed light, 0.05% cyclosporine A eye drops, and 3% diquafosol sodium eye drops in the treatment of moderate to severe dry eye: A prospective cohort study.","finding":"","journal":"Medicine","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"P2Y purinoceptor 2","category":"target"},{"label":"P2RY2","category":"gene"},{"label":"P2RY4","category":"gene"},{"label":"Active","category":"status"},{"label":"Tear film insufficiency","category":"indication"},{"label":"Santen Pharmaceutical","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Santen Pharmaceutical","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DIQUAFOSOL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:49:49.958076+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:49:56.339196+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DIQUAFOSOL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:49:56.642651+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5398873/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:49:57.355323+00:00"}},"allNames":"up4u","offLabel":[],"synonyms":["diquafosol","diquafosol sodium","diquafosol tetrasodium","INS365","INS-365","Up4U","KPY 998","DE 089"],"timeline":[{"date":"2010-02-09","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Santen Pharmaceutical)"}],"approvals":[{"date":"2010-02-09","orphan":false,"company":"Santen Pharmaceutical","regulator":"PMDA"}],"brandName":"Up4U","ecosystem":[{"indication":"Tear film insufficiency","otherDrugs":[{"name":"ciclosporin","slug":"ciclosporin","company":"Novartis"},{"name":"crospovidone","slug":"crospovidone","company":""},{"name":"lifitegrast","slug":"lifitegrast","company":"Shire Dev Llc"},{"name":"lutein","slug":"lutein","company":""}],"globalPrevalence":null}],"mechanism":{"target":"P2Y purinoceptor 2","targets":[{"gene":"P2RY2","source":"DrugCentral","target":"P2Y purinoceptor 2","protein":"P2Y purinoceptor 2"},{"gene":"P2RY4","source":"DrugCentral","target":"P2Y purinoceptor 4","protein":"P2Y purinoceptor 4"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Up4U acts as a P2Y purinoceptor 2 agonist, binding to the receptor and activating a signaling cascade that leads to increased tear production through the stimulation of lacrimal gland secretion."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4900","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DIQUAFOSOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DIQUAFOSOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:47:21.018085","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:49:58.994360+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"diquafosol","indications":{"approved":[{"name":"Tear film insufficiency","source":"DrugCentral","snomedId":46152009,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07397949","phase":"PHASE4","title":"Rebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2026-03","conditions":["Dry Eye Disease (DED)","Cataract"],"enrollment":60,"completionDate":"2027-03"},{"nctId":"NCT07397936","phase":"PHASE4","title":"Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract Surgery","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2024-08-01","conditions":["Dry Eye Disease (DED)","Cataract"],"enrollment":55,"completionDate":"2025-05-01"},{"nctId":"NCT07297316","phase":"PHASE4","title":"Immediate Therapeutic Effects of Diquafosol and Rebamipide in Dry Eye Disease","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2022-10-03","conditions":["Dry Eye Disease (DED)"],"enrollment":30,"completionDate":"2024-08-30"},{"nctId":"NCT06903884","phase":"PHASE3","title":"3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-12-30","conditions":["Vernal Keratoconjunctivitis"],"enrollment":94,"completionDate":"2028-12-31"},{"nctId":"NCT07122635","phase":"","title":"Effectiveness of Dry Eye Treatment With Diquafosol Sodium 3% After Phaco Surgery","status":"COMPLETED","sponsor":"Le Xuan Cung","startDate":"2024-10-03","conditions":["Dry Eye Disease"],"enrollment":60,"completionDate":"2025-03-31"},{"nctId":"NCT07097922","phase":"NA","title":"Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients With Dry Eye After LASIK","status":"NOT_YET_RECRUITING","sponsor":"He Eye Hospital","startDate":"2025-08-01","conditions":["Dry Eye"],"enrollment":140,"completionDate":"2026-05-01"},{"nctId":"NCT05682547","phase":"NA","title":"Diquafosol vs Hyaluronic Acid for Diabetic Dry Eye","status":"COMPLETED","sponsor":"He Eye Hospital","startDate":"2022-12-01","conditions":["Diabetic Eye Problems"],"enrollment":99,"completionDate":"2023-06-30"},{"nctId":"NCT06427031","phase":"PHASE3","title":"Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients","status":"COMPLETED","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2023-07-14","conditions":["Dry Eye","Dry Eye Syndromes"],"enrollment":271,"completionDate":"2024-07-03"},{"nctId":"NCT06852105","phase":"NA","title":"Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients with Dry Eye After Trans-PRK","status":"NOT_YET_RECRUITING","sponsor":"He Eye Hospital","startDate":"2025-02-28","conditions":["Dry Eye","Tear Break-Up Time"],"enrollment":76,"completionDate":"2026-05-31"},{"nctId":"NCT06560580","phase":"NA","title":"Ditefossol Sodium 3% Eye Drops in Patients With Dry Eye","status":"COMPLETED","sponsor":"Tianjin Eye Hospital","startDate":"2021-11-15","conditions":["Dry Eye Disease"],"enrollment":97,"completionDate":"2024-07-25"},{"nctId":"NCT06537349","phase":"NA","title":"Effects of 3% Diquafosol on Tear Film and Vision-related Quality of Life in Orthokeratology Lens Related Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"He Eye Hospital","startDate":"2024-08-15","conditions":["Dry Eye"],"enrollment":30,"completionDate":"2024-12-31"},{"nctId":"NCT06158984","phase":"NA","title":"Managing Dry Eye in Patients Using Glaucoma Drops","status":"COMPLETED","sponsor":"He Eye Hospital","startDate":"2023-10-03","conditions":["Dry Eye"],"enrollment":60,"completionDate":"2023-12-02"},{"nctId":"NCT06158997","phase":"NA","title":"Safety and Effectiveness of EyePeace on Signs and Symptoms of Dry Eye Disease","status":"UNKNOWN","sponsor":"He Eye Hospital","startDate":"2023-12-03","conditions":["Evaporative Dry Eye"],"enrollment":60,"completionDate":"2024-04-01"},{"nctId":"NCT06146881","phase":"PHASE2","title":"Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in Indonesia","status":"UNKNOWN","sponsor":"Indonesia University","startDate":"2022-10-02","conditions":["Dry Eye Disease"],"enrollment":70,"completionDate":"2024-03-15"},{"nctId":"NCT05694026","phase":"NA","title":"Management of DE With IPL in Combination With DQS","status":"COMPLETED","sponsor":"He Eye Hospital","startDate":"2023-03-01","conditions":["Dry Eye"],"enrollment":360,"completionDate":"2023-07-01"},{"nctId":"NCT05383612","phase":"NA","title":"To Evaluate the Efficacy of Diquafosol Sodium in the Treatment of MGD in Different Treatment Pattern","status":"UNKNOWN","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2022-08-05","conditions":["Dry Eye","Meibomian Gland Dysfunction"],"enrollment":140,"completionDate":"2025-05-20"},{"nctId":"NCT05720754","phase":"NA","title":"Temperature on Evaporative Dry Eye","status":"UNKNOWN","sponsor":"He Eye Hospital","startDate":"2023-04-02","conditions":["Dry Eye"],"enrollment":45,"completionDate":"2023-08-01"},{"nctId":"NCT04980144","phase":"NA","title":"Diquafosol Ophthalmic Solution for Dry Eye Symptoms","status":"UNKNOWN","sponsor":"He Eye Hospital","startDate":"2023-03-03","conditions":["Diabetic Eye Problems"],"enrollment":101,"completionDate":"2023-11-01"},{"nctId":"NCT05193331","phase":"NA","title":"Use of 3% Diquafosol Topical Ophthalmic Solution for Diabetic Dry Eye","status":"UNKNOWN","sponsor":"He Eye Hospital","startDate":"2023-04-01","conditions":["Diabetic Eye Problems"],"enrollment":70,"completionDate":"2023-11-01"},{"nctId":"NCT05456061","phase":"NA","title":"Effect of ADDE on Tear Interferometry","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2018-08-01","conditions":["Tear","Dry Eye Syndromes"],"enrollment":152,"completionDate":"2022-01-31"},{"nctId":"NCT04668118","phase":"PHASE4","title":"The Effect of 3% Diquafosol Ophthalmic Solution on Visual Display Terminal-associated Dry Eye","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2021-02-01","conditions":["Dry Eye Syndromes","Computer Vision Syndrome","Asthenopia"],"enrollment":68,"completionDate":"2023-03-25"},{"nctId":"NCT05346783","phase":"PHASE1,PHASE2","title":"Comparing Efficacy and Safety of TJO-083 in Dry Eye Disease Patients","status":"UNKNOWN","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2021-10-14","conditions":["Dry Eye Syndromes"],"enrollment":98,"completionDate":"2023-06"},{"nctId":"NCT04952987","phase":"","title":"Dry Eye Management With 3% Diquafosol Before and After Cataract Surgery","status":"UNKNOWN","sponsor":"Mun Wai Lee","startDate":"2021-01-01","conditions":["Dry Eye"],"enrollment":50,"completionDate":"2021-12-30"},{"nctId":"NCT04548427","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of CKD-352","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-09-22","conditions":["Dry Eye Disease"],"enrollment":283,"completionDate":"2021-05-07"},{"nctId":"NCT03640351","phase":"NA","title":"Clinical Effects of Diquas-S for Patients With Dry Eye After Cataract Surgery","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2017-08-15","conditions":["Dry Eye","Cataract Surgery"],"enrollment":150,"completionDate":"2019-02-13"},{"nctId":"NCT02618304","phase":"NA","title":"Changes of Tear-film Lipid Layer Thickness and Ocular Aberration After Treatment of Meibomian Gland Dysfunction","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2015-04-20","conditions":["Meibomian Gland Dysfunction"],"enrollment":45,"completionDate":"2016-02-19"},{"nctId":"NCT00403715","phase":"PHASE3","title":"Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-02","conditions":["Dry Eye Disease"],"enrollment":500,"completionDate":"2002-09"},{"nctId":"NCT00404131","phase":"PHASE3","title":"Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-03","conditions":["Dry Eye Disease"],"enrollment":500,"completionDate":"2001-12"},{"nctId":"NCT02608489","phase":"NA","title":"Clinical Effects and Safety of 3% Diquafosol After Cataract Surgery","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","startDate":"2014-01","conditions":["Dry Eye Syndromes"],"enrollment":86,"completionDate":"2015-01"},{"nctId":"NCT00403975","phase":"PHASE3","title":"Study of Diquafosol Tetrasodium Ophthalmic Solution in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06","conditions":["Dry Eye Disease"],"enrollment":640,"completionDate":"2004-11"},{"nctId":"NCT01381731","phase":"PHASE2","title":"A Double-masked, Randomized, Placebo-controlled,Pilot Study of Diquafosol Tetrasodium in Subjects Following Photorefractive Keratectomy (PRK)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-04","conditions":["Photorefractive Keratectomy"],"enrollment":14,"completionDate":"2005-06"},{"nctId":"NCT00037661","phase":"PHASE3","title":"Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-04","conditions":["Keratoconjunctivitis Sicca"],"enrollment":222,"completionDate":"2003-03"},{"nctId":"NCT00680108","phase":"PHASE2","title":"A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1999-09","conditions":["Dry Eye Disease"],"enrollment":62,"completionDate":"2000-05"},{"nctId":"NCT00679718","phase":"PHASE2","title":"A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2000-01","conditions":["Dry Eye Disease"],"enrollment":150,"completionDate":"2000-07"},{"nctId":"NCT00831662","phase":"PHASE3","title":"The Effects of Diquafosol Tetrasodium Ophthalmic Solution, 2% in Subjects With Dry Eye Disease (P08637)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-01","conditions":["Dry Eye Disease"],"enrollment":490,"completionDate":"2009-12"},{"nctId":"NCT00600288","phase":"PHASE3","title":"Study of the Effect of Diquafosol Tetrasodium Ophthalmic Solution, 2% Versus Placebo in Dry Eye Subjects (P08634)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01","conditions":["Dry Eye Disease"],"enrollment":261,"completionDate":"2008-05"},{"nctId":"NCT01101984","phase":"NA","title":"Study of DE-089 Ophthalmic Solution in Patients With Dry Eye","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2010-02","conditions":["Dry Eye"],"enrollment":400,"completionDate":"2012-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"018489","UNII":"7828VC80FJ","CHEBI":"CHEBI:27791","INN_ID":"8326","UMLSCUI":"C1955479","chemblId":"CHEMBL5398873","ChEMBL_ID":"CHEMBL221326","KEGG_DRUG":"D03864","DRUGBANK_ID":"DB15919","PUBCHEM_CID":"148197","IUPHAR_LIGAND_ID":"1736","SECONDARY_CAS_RN":"211427-08-6","MESH_SUPPLEMENTAL_RECORD_UI":"C403315"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Santen Pharmaceutical","relationship":"Current Owner"}],"publicationCount":220,"therapeuticAreas":["Ophthalmology"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 10","pmid":"41804812","title":"Efficacy of Topical Cyclosporine Versus Topical Diquafosol in Treating Dry Eye Disease: A Systematic Review and Meta-Analysis.","journal":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics"},{"date":"2025 Oct-Dec","pmid":"41523136","title":"Integrating secretagogues into clinical dry eye care: Insights from Asian clinical experience.","journal":"Taiwan journal of ophthalmology"},{"date":"2025 Oct-Dec","pmid":"41523116","title":"Restoring the mucin barrier: Advances in secretagogue therapies for ocular surface disorders.","journal":"Taiwan journal of ophthalmology"},{"date":"2025 Dec 18","pmid":"41464847","title":"Preoperative Diquafosol vs. Intense Pulsed Light with Gland Expression for MGD: Effects on Refractive Accuracy and Tear Film Stability in Cataract Surgery.","journal":"Journal of clinical medicine"},{"date":"2025 Dec 5","pmid":"41366894","title":"Comparison of the efficacy of intense pulsed light, 0.05% cyclosporine A eye drops, and 3% diquafosol sodium eye drops in the treatment of moderate to severe dry eye: A prospective cohort study.","journal":"Medicine"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Santen Pharmaceutical","companyId":"santen-pharmaceutical","modality":"Small molecule","firstApprovalDate":"2010","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2010-02-09T00:00:00.000Z","mah":"Santen Pharmaceutical","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:49:58.994360+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}